US4130648A - 5-Fluorouracil derivatives and antitumor preparations containing the same - Google Patents
5-Fluorouracil derivatives and antitumor preparations containing the same Download PDFInfo
- Publication number
- US4130648A US4130648A US05/860,319 US86031977A US4130648A US 4130648 A US4130648 A US 4130648A US 86031977 A US86031977 A US 86031977A US 4130648 A US4130648 A US 4130648A
- Authority
- US
- United States
- Prior art keywords
- fluorouracil
- derivative
- carbonyl
- compound
- tocopheryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- This invention relates to a novel 5-fluorouracil derivative having the general formula (I) ##STR2## wherein R 1 , R 2 and R 3 each represent hydrogen atom or methyl group, and R 4 represents a straight or branched alkyl or alkenyl group.
- R 1 , R 2 and R 3 each represent hydrogen atom or methyl group
- R 4 represents a straight or branched alkyl or alkenyl group.
- This invention also relates to antitumor preparations containing said novel derivative.
- alkylating agents such as busulfan, chlorambutyl, merphalan and the like
- antimetabolics such as methotrexate, 6-mercaptopurine, 6-mercaptopurine ribo-nucleoside, 5-fluorouracil, and the like, for chemotherapeutics to various malignant tumors such as gastric cancer, hepatoma, bladder cancer, seminoma, leukemia, lymphosarcoma, breast cancer, lung cancer, uterine cancer and the like.
- 5-fluorouracil has clinical utility.
- FT-207 shows remarkably lower toxicity, i.e., 1/7-1/5 of that of 5-fluorouracil per se and less antitumor activity.
- a considerably long period of time is required to obtain remission by administration of FT-207 alone.
- novel 5-fluorouracil derivatives which show less toxicity than the known 5-fluorouracil, and also FT-207 and maintain high antitumor activity. And, we found that the desired object is attained by the derivatives (I) according to this invention.
- An object of this invention is therefore to provide novel 5-fluorouracil derivatives having the general formula (I) as described above.
- Another object of this invention is to provide a process for the preparation of 5-fluorouracil derivatives.
- a further object of this invention is to provide novel antitumor preparations containing the 5-fluorouracil derivatives.
- a still further object of this invention is to provide a method for treating various malignant tumors such as gastric cancer, hepatoma, bladder cancer, seminoma, leukemia, lymphosarcoma, breast cancer, lung cancer, uterine cancer, and the like.
- 5-fluorouracil is reacted with a carbonate of 6-chromanol derivative having the general formula (II): ##STR3## wherein R 1 , R 2 , R 3 and R 4 have the same meanings as defined above, and X represents a halogen atom or a lower alkoxyl group, to obtain the desired derivatives (I).
- the starting material, 5-fluorouracil in a form of an alkali metal salt thereof.
- the reaction can advantageously progress by using an organic solvent such as dimethyl formamide, dimethyl acetamide, and the like.
- the reaction proceeds in an equimolar state and preferably at a temperature ranging from room temperature to about 50° C.
- FT-207 and 5-fluorouracil are selected as standard drugs.
- Compound A was administered as a solution of soybean oil and 5-FU was administered as saline solution, at 24 hours after the implantation.
- Soybean oil was administered as control for the Compound A.
- Saline solution was administered as control for 5-FU.
- TPCV total packed cell volumes
- ED 50 of the Compound A of this invention is about 170 mg/Kg and its safety index (LD 50 /ED 50 ) is more than 24, while ED 50 of 5-FU is about 25 mg/Kg and its safety index is about 5. These results show that Compound A is less toxic as an antitumor agent.
- Compound A was administered as a solution of soybean oil at 24 hours after the implantation.
- Soybean oil was administered as control for Compound A.
- Each of the drugs was orally administered as a solution of safflower oil 3 hours after the implantation.
- Safflower oil was administered as control for each of the drugs.
- the minimum effective dose of Compound A is about 250 mg/Kg, that of FT-207 is about 100 mg/Kg, and that of 5-FU is about 20 mg/Kg.
- the ratios of the minimum effective dose to toxic dose (LD 50 ) in each of the drugs Compound A gives less than 1/16; FT-207 gives about 1/10; and 5-FU gives about 1/6. Therefore, the availability of the Compound A is higher than those of the other two drugs.
- Compound A was intraperitoneally administered as a solution of medium chain triglyceride (MCT) at 24 hours after the implantation.
- MCT medium chain triglyceride
- Each of 5-FU and FT-207 was also intraperitoneally administered as a saline solution at 24 hours after the implantation.
- MCT was administered as control for Compound A.
- Saline solution was administered as controls for 5-FU and FT-207.
- the ratio of said dose to the LD 50 in the Compound A is smaller than that of 5-FU. Therefore, the availability of the Compound A is higher than that of 5-FU.
- Compound A was intraperitoneally administered in CDF 1 mice (female, 8-10 weeks old) as a solution of MCT, before the implantation as shown in Table 6.
- FT-207 and 5-FU were intraperitoneally administered as a saline solution, before the implantation as shown in Table 6.
- MCT was administered as control for Compound A.
- Saline solution was administered as controls for FT-207 and 5-FU.
- the derivatives of this invention have very lower toxicity and a broader range between toxic dose and effective dose than those of 5-FU and FT-207. Duration of the derivatives of this invention is more effective than with 5-FU and FT-207. In these points, the derivatives of this invention are excellent antitumor agents.
- Dose of the derivatives of this invention as antitumor agents amount to about 1-200 mg/Kg per day, preferably 5-100 mg/Kg for adult.
- the derivatives of this invention may be administered either orally or parenterally.
- administration form powder, granule, tablet, capsule, liquid for injection, suppository and ointment can be available.
- formulations can be prepared by using a conventional excipient by means of a conventional process.
- a suspension was prepared by adding 10.3 g (0.13 mols) of 55% oily sodium hydride to 100 ml of dimethyl formamide. The suspension was cooled to below 5° C. 150 ml of dimethyl formamide solution containing 16.9 g (0.13 mols) of 5-fluorouracil were added slowly dropwise to the suspension while stirring for 30 minutes, and the mixed solution was further kept for one hour at the same condition. To the solution, 100 ml of dimethyl formamide solution containing 64.1 g (0.13 mols) of d,l- ⁇ -tocopheryl chloroformate were added slowly dropwise for 30 minutes. The solution was heated to 40° C. and stirred for additional one hour.
- the reaction solution was allowed to cool to a room temperature, and subjected to the filtration.
- the filtrate was concentrated under a reduced pressure.
- the resulting residue in the amount of 76 g was extracted twice with 300 ml of benzene, respectively.
- the benzene extract was concentrated under a reduced pressure.
- the resulting residue in the amount of 71 g was recrystallized from ethanol to obtain the object material in a white crystalline powder having a melting point of 119°-120° C.
- N 1 -d,l- ⁇ -tocopheryl carbonyl-5-fluorouracil, micro-crystallized cellulose, corn starch and lactose were mixed altogether.
- Aqueous polyvinyl pyrolidone solution was added as a binder to this mixture, and the whole was granulated by a conventional process. These granules were filled in hard gelatinous capsules, to form the capsules.
- N 1 -d,l- ⁇ -tocopheryl carbonyl-5-fluorouracil, micro-crystallized cellulose, corn starch, lactose and calcium carboxymethyl cellulose were mixed altogether.
- Aqueous polyvinyl pyrolidone solution was added as a binder to said mixture, and the whole was granulated by a conventional process.
- the granules were admixed with the talc, to form tablets of 200 mg per tablet.
- a liquid for injection was prepared by a conventional method.
- N 1 -d,l- ⁇ -tocopheryl carbonyl-5-fluorouracil Forty grams of N 1 -d,l- ⁇ -tocopheryl carbonyl-5-fluorouracil were dissolved in one liter of O. D. O. (medium chain triglyceride produced and sold by Nisshin Oil Co., Ltd., Japan). This solution was put in a film of soft capsule of gelatine to obtain a suppository.
- O. D. O. medium chain triglyceride produced and sold by Nisshin Oil Co., Ltd., Japan
Abstract
Novel 5-fluorouracil derivatives of the general formula: ##STR1## wherein R1, R2 and R3 each represent hydrogen atom or methyl group, and R4 represents a straight or branched alkyl or alkenyl group, which has low toxicity and improved antitumor activity, and novel antitumor preparations containing the said 5-fluorouracil derivative.
Description
This invention relates to a novel 5-fluorouracil derivative having the general formula (I) ##STR2## wherein R1, R2 and R3 each represent hydrogen atom or methyl group, and R4 represents a straight or branched alkyl or alkenyl group. This invention also relates to antitumor preparations containing said novel derivative.
Heretofore, there were used alkylating agents such as busulfan, chlorambutyl, merphalan and the like; and antimetabolics such as methotrexate, 6-mercaptopurine, 6-mercaptopurine ribo-nucleoside, 5-fluorouracil, and the like, for chemotherapeutics to various malignant tumors such as gastric cancer, hepatoma, bladder cancer, seminoma, leukemia, lymphosarcoma, breast cancer, lung cancer, uterine cancer and the like. Among these chemotherapeutics, 5-fluorouracil has clinical utility. It is advantageous in that it is effective on many kinds of tumors; its effect is increased by combination therapies with other antitumor drug(s); and the effect of radiotherapy is enhanced by using 5-fluorouracil. However, close attention is required, because 5-fluorouracil shows relatively severe toxicity at the effective dosage. Under the circumstances, many investigations were made to find more useful 5-fluorouracil derivatives which were less toxic to the host and showed more activity to tumors. As a result of said investigation, N1 -(2'-tetrahydrofurfuryl)-5-fluorouracil (FT-207) was found.
FT-207 shows remarkably lower toxicity, i.e., 1/7-1/5 of that of 5-fluorouracil per se and less antitumor activity. However, in clinical application, a considerably long period of time is required to obtain remission by administration of FT-207 alone. We found novel 5-fluorouracil derivatives which show less toxicity than the known 5-fluorouracil, and also FT-207 and maintain high antitumor activity. And, we found that the desired object is attained by the derivatives (I) according to this invention.
An object of this invention is therefore to provide novel 5-fluorouracil derivatives having the general formula (I) as described above.
Another object of this invention is to provide a process for the preparation of 5-fluorouracil derivatives.
A further object of this invention is to provide novel antitumor preparations containing the 5-fluorouracil derivatives.
A still further object of this invention is to provide a method for treating various malignant tumors such as gastric cancer, hepatoma, bladder cancer, seminoma, leukemia, lymphosarcoma, breast cancer, lung cancer, uterine cancer, and the like.
Other objects of this invention will be understood from the following descriptions.
There are various processes for the synthesis of said derivatives (I) depending on their chemical structures. One of the processes is explained as follows:
5-fluorouracil is reacted with a carbonate of 6-chromanol derivative having the general formula (II): ##STR3## wherein R1, R2, R3 and R4 have the same meanings as defined above, and X represents a halogen atom or a lower alkoxyl group, to obtain the desired derivatives (I). In this reaction, it is preferable to use the starting material, 5-fluorouracil, in a form of an alkali metal salt thereof. The reaction can advantageously progress by using an organic solvent such as dimethyl formamide, dimethyl acetamide, and the like. The reaction proceeds in an equimolar state and preferably at a temperature ranging from room temperature to about 50° C.
The following shows the data of acute toxicities and antitumor activities of N1 -d,l-α-tocopheryl carbonyl-5-fluorouracil according to this invention (hereinafter referred to the Compound A of this invention). FT-207 and 5-fluorouracil (hereinafter abbreviated to 5-FU) are selected as standard drugs.
LD50 (mg/Kg) after three weeks observation in CDF1 mice (female, 8-10 weeks old)
Table 1
______________________________________
Subcuta-
Intravenous
Intraperito-
neous Oral
administ-
neal administ-
administ-
admini-
ration ration ration stration
______________________________________
Compound A
-- >4000 >4000 >4000
FT-207 750 800 830 930
5-FU 135 150 175 120
______________________________________
From Table 1, it is found that Compound A has a lower acute toxicity than FT-207 and 5-FU.
In addition, similar results were also obtained for the acute toxocity (LD50) in ICR/JCL mice.
(1) Inhibitory effect on the growth of S-180 ascites form (Intraperitoneal administration)
Implantation
106 cells of S-180 were intraperitoneally implanted in ICR/JCL mice (female, 8-10 weeks old).
Administration
To test groups:
Compound A was administered as a solution of soybean oil and 5-FU was administered as saline solution, at 24 hours after the implantation.
To control groups:
Soybean oil was administered as control for the Compound A. Saline solution was administered as control for 5-FU.
Observation
Ten days after the implantation of the tumor cells, the total packed cell volumes (TPCV) were measured. The measurement of TPCV was carried out in accordance with Hoshi, A. et al., Chemical & Pharmaceutical Bulletion 17 (4), 848-850 (1969). The results are shown in Table 2, wherein T/C % means the ratio of the TPCV of the test groups to that of the control group.
Table 2
______________________________________
Drugs Dose Number of Tumor growth
administered
(mg/Kg) animals (TPCV : T/C %)
______________________________________
Soybean oil
-- 16 100
(control)
4000 8 0
Compound A
2000 8 0
1000 8 0
500 8 3.3
250 8 30.4
125 8 64.7
62 8 77.5
Saline
solution -- 16 100
(control)
500 8 (died)
5-FU 250 8 (died)
125 8 4.3
68 8 26.4
34 8 43.3
______________________________________
It is understood from Tables 1 and 2 that ED50 of the Compound A of this invention is about 170 mg/Kg and its safety index (LD50 /ED50) is more than 24, while ED50 of 5-FU is about 25 mg/Kg and its safety index is about 5. These results show that Compound A is less toxic as an antitumor agent.
(2) Survival effect
Implantation
106 cells of S-180 were intraperitoneally implanted in ICR/JCL mouse (female, 6-8 weeks old).
Administration
To test group:
Compound A was administered as a solution of soybean oil at 24 hours after the implantation.
To control group:
Soybean oil was administered as control for Compound A.
Observation
Survival days after implantation was measured. The increase in life-span over control groups (ILS = T/C % - 100) was calculated. The results are shown in Table 3.
Table 3
______________________________________
Mean ILS (%)
Drugs Dose Number of survival
over
administered
(mg/Kg) animals days control
______________________________________
Soybean oil
(Control)
-- 8 13.8 0
4000 8 39.0 182.6
Compound A
2000 8 36.0 160.9
1000 8 43.5 215.2
500 8 33.0 139.1
______________________________________
It is confirmed from Table 3 that Compound A exhibits a marked effect by a single administration of 1/8 LD50.
(3) Effect on growth of solid tumor by oral administration
Implantation
1.8 × 106 cells of S-180 were implanted subcutaneously in ICR/JCL mice (female, 6-8 weeks old).
Administration
To test group:
Each of the drugs was orally administered as a solution of safflower oil 3 hours after the implantation.
To control group:
Safflower oil was administered as control for each of the drugs.
Observation
Twenty days after, the tumor weight was measured, and the ratio of the tumor weight to that of the control group (T/C %) was calculated. The results are shown in Table 4.
Table 4
______________________________________
Drugs Dose Number of Tumor growth
administered
(mg/Kg) animals (weight : T/C %)
______________________________________
Safflower oil
-- 8 100
(control)
62 8 106
125 8 87
Compound A
250 8 33
500 8 47
1000 8 38
2000 8 36
25 8 148
50 8 269
FT-207 100 8 58
200 8 43
400 8 34
10 8 156
5-FU 20 8 55
40 8 52
80 8 63
______________________________________
From Table 4, the minimum effective dose of Compound A is about 250 mg/Kg, that of FT-207 is about 100 mg/Kg, and that of 5-FU is about 20 mg/Kg. As for the ratios of the minimum effective dose to toxic dose (LD50) in each of the drugs, Compound A gives less than 1/16; FT-207 gives about 1/10; and 5-FU gives about 1/6. Therefore, the availability of the Compound A is higher than those of the other two drugs.
(1) Survival effect
Implantation
105 cells of L-1210 leukemia were intraperitoneally implanted in CDF1 mice (female, 8-10 weeks old).
Administration
To test group:
Compound A was intraperitoneally administered as a solution of medium chain triglyceride (MCT) at 24 hours after the implantation.
Each of 5-FU and FT-207 was also intraperitoneally administered as a saline solution at 24 hours after the implantation.
To control group:
MCT was administered as control for Compound A.
Saline solution was administered as controls for 5-FU and FT-207.
Observation
Mean survival time after the implantation was determined, and the increase in life-span (ILS) over controls was calculated. The results are shown in Table 5.
Table 5
______________________________________
Mean ILS %
Drugs Dose Number of survival
over
administered
(mg/Kg) animals days controls
______________________________________
MCT -- 6 7.0 0
(control)
125 6 7.0 0
250 6 8.0 14
Compound A
500 6 9.8 40
1000 6 12.1 73
2000 6 12.5 79
4000 6 13.5 93
Saline -- 27 7.0 0
15 6 8.1 15
5-FU 30 6 8.8 25
(Saline) 60 6 9.7 38
FT-207 50 6 7.0 0
(Saline) 200 6 7.1 1
______________________________________
From Table 5, it cannot be confirmed that FT-207 is effective in a dose of about 1/4 LD50. On the contrary, it can be confirmed that Compound A is effective even in a dose of about 1/8 LD50.
Additionally, in comparison of the dose of the Compound A with that of 5-FU, wherein the dose shows the corresponding increase in life-span (ILS), the ratio of said dose to the LD50 in the Compound A is smaller than that of 5-FU. Therefore, the availability of the Compound A is higher than that of 5-FU.
(2) Duration of antitumor activity
Administration
To test group:
Compound A was intraperitoneally administered in CDF1 mice (female, 8-10 weeks old) as a solution of MCT, before the implantation as shown in Table 6.
Each of FT-207 and 5-FU was intraperitoneally administered as a saline solution, before the implantation as shown in Table 6.
To control groups:
MCT was administered as control for Compound A.
Saline solution was administered as controls for FT-207 and 5-FU.
Implantation
105 cells of L-1210 leukemia were intraperitoneally implanted in the mice.
Observation
Survival days after the implantation were counted. The results were shown in Table 6.
Table 6
______________________________________
Administration
time of drugs
(number of days
Number Mean
Drugs before tumor of servival
administered
implantation)
animals days
______________________________________
No admini- -- 7 9.1
stration
0 4 9.0
1 8 10.3
MCT 2 7 10.1
(control) 3 7 10.1
4 7 9.9
6 5 9.0
0 8 11.6
Compound A 1 6 13.0
(Dose : 1000
2 8 16.4
mg/Kg) 3 8 11.8
4 7 11.2
6 4 13.5
1 5 8.8
Saline 2 5 9.0
4 5 9.0
FT-207 (Saline)
1 5 8.8
(Dose : 200 2 5 9.0
mg/Kg) 4 5 9.0
5-FU (Saline)
1 5 9.0
(Dose 50 mg/Kg)
2 5 9.0
4 5 8.8
______________________________________
In Table 6, it is shown that Compound A exhibits survival effects by administration either on the same day of the implantation of the tumor cells, or on 1-6 days prior to the implantation, and that Compound A shows antitumor effects for 6 days.
As described above, the derivatives of this invention have very lower toxicity and a broader range between toxic dose and effective dose than those of 5-FU and FT-207. Duration of the derivatives of this invention is more effective than with 5-FU and FT-207. In these points, the derivatives of this invention are excellent antitumor agents.
Dose of the derivatives of this invention as antitumor agents amount to about 1-200 mg/Kg per day, preferably 5-100 mg/Kg for adult.
The derivatives of this invention may be administered either orally or parenterally. As the administration form, powder, granule, tablet, capsule, liquid for injection, suppository and ointment can be available.
These formulations can be prepared by using a conventional excipient by means of a conventional process.
The following examples are illustrative of this invention, and are not to be construed as a limitation of the invention, parts and percentages being by weight unless otherwise specified.
A suspension was prepared by adding 10.3 g (0.13 mols) of 55% oily sodium hydride to 100 ml of dimethyl formamide. The suspension was cooled to below 5° C. 150 ml of dimethyl formamide solution containing 16.9 g (0.13 mols) of 5-fluorouracil were added slowly dropwise to the suspension while stirring for 30 minutes, and the mixed solution was further kept for one hour at the same condition. To the solution, 100 ml of dimethyl formamide solution containing 64.1 g (0.13 mols) of d,l-α-tocopheryl chloroformate were added slowly dropwise for 30 minutes. The solution was heated to 40° C. and stirred for additional one hour. After the stirring, the reaction solution was allowed to cool to a room temperature, and subjected to the filtration. The filtrate was concentrated under a reduced pressure. The resulting residue in the amount of 76 g was extracted twice with 300 ml of benzene, respectively. The benzene extract was concentrated under a reduced pressure. The resulting residue in the amount of 71 g was recrystallized from ethanol to obtain the object material in a white crystalline powder having a melting point of 119°-120° C.
Yield: 64.7 g (85%)
Elementary analysis of the compound having the presumable formula C34 H51 FN2 O5 gives the following data.
______________________________________
C H N
______________________________________
Calculated (%)
69.59 8.76 4.77
Found (%) 69.44 8.70 4.79
______________________________________
Infrared absorption spectrum: (KBr method)
Three absorption bands due to carbonyl group are observed in a range of 1700-1770 cm-1.
Nuclear magnetic resonance spectrum: (CDCl3)
δ 8.22 (d:1, J5-6 = 8.0Hz, H6)
2.60 (t:2 J = 7Hz)
2.09-2.04 (s:9 Phenylmethyl group)
1.80 (t:2, J = 7Hz)
1.60-1.18 (m:18)
0.9-0.8 (d:15)
Mass spectrum: M+ = 586
2.47 g (0.019 mols) of 5-fluorouracil and 5.13 g (0.019 mols) of 2,2,5,7,8-pentamethylchromanyl-6-chloroformate were subjected to the reaction and the subsequent treatment according to the procedure of Example 1. The object material was thus obtained in a form of a white crystalline powder having a melting point of 208°-210° C.
Yield: 4.9 g (68.5%)
Elementary analysis of the compound having the presumable formula C19 H21 FN2 O5 gives the following data.
______________________________________
C H N
______________________________________
Calculated (%)
60.63 5.60 7.40
Found (%) 60.75 5.58 7.41
______________________________________
Infrared absorption spectrum: (KBr method)
Three absorption bands due to the carbonyl group were observed in a range of 1700-1770 cm-1.
Nuclear magnetic resonance spectrum: (deutero pyridine)
δ 8.24 (d = 1 J5-6 = 8.0Hz, H6)
2.62 (t = 2 J = 7Hz)
2.08-2.04 (s = 9 phenylmethyl group)
1.82 (t = 2, J = 7Hz)
1.32 (s = 6 methyl group)
The compounds according to this invention are shown as examples in the following table.
__________________________________________________________________________
##STR4##
Molecular
Elementary analysis (%)
formula Calculated
Example Melting Found
No. R.sub.1
R.sub.2
R.sub.3
R.sub.4 point (° C)
C H N F Remarks
__________________________________________________________________________
3 CH.sub.3
CH.sub.3
CH.sub.3
##STR5##
##STR6##
##STR7##
##STR8##
##STR9##
##STR10##
d,l - form
4 CH.sub.3
CH.sub.3
CH.sub.3
##STR11##
##STR12##
##STR13##
##STR14##
##STR15##
##STR16##
d,l - form
5 H CH.sub.3
CH.sub.3
##STR17##
##STR18##
##STR19##
##STR20##
##STR21##
##STR22##
d - form
6 H H CH.sub.3
##STR23##
##STR24##
##STR25##
##STR26##
##STR27##
##STR28##
d - form
7 CH.sub.3
CH.sub.3
CH.sub.3
##STR29##
##STR30##
##STR31##
##STR32##
##STR33##
##STR34##
d - form
8 CH.sub.3
CH.sub.3
CH.sub.3
##STR35##
##STR36##
##STR37##
##STR38##
##STR39##
##STR40##
d,l -
__________________________________________________________________________
form
______________________________________
N.sub.1 -d,1-α-tocopheryl carbonyl-5-fluorouracil
80 g
Micro-crystallized cellulose
40 g
Corn starch 15 g
Lactose 12 g
Polyvinyl pyrolidone 3 g
Total 150 g
______________________________________
In accordance with the above formulation, N1 -d,l-α-tocopheryl carbonyl-5-fluorouracil, micro-crystallized cellulose, corn starch and lactose were mixed altogether. Aqueous polyvinyl pyrolidone solution was added as a binder to this mixture, and the whole was granulated by a conventional process. These granules were filled in hard gelatinous capsules, to form the capsules.
______________________________________
N.sub.1 -d,l-α-tocopheryl carbonyl-5-fluorouracil
100 g
Micro-crystallized cellulose
40 g
Corn starch 14 g
Lactose 20 g
Calcium carboxymethyl cellulose
10 g
Polyvinyl pyrolidone 6 g
Talc 10 g
Total 200 g
______________________________________
According to the above formulation, N1 -d,l-α-tocopheryl carbonyl-5-fluorouracil, micro-crystallized cellulose, corn starch, lactose and calcium carboxymethyl cellulose were mixed altogether. Aqueous polyvinyl pyrolidone solution was added as a binder to said mixture, and the whole was granulated by a conventional process. The granules were admixed with the talc, to form tablets of 200 mg per tablet.
______________________________________
N.sub.1 -d-γ-tocopheryl carbonyl-5-fluorouracil
10 g
Nikko HCO-60 (Trade Mark, Nikko Chemical
40 g
Company, Japan)
Propylene glycol 80 g
Sorbitol 20 g
Distilled water sufficient to make up total
1 liter
______________________________________
According to the above formulation, a liquid for injection was prepared by a conventional method.
Forty grams of N1 -d,l-α-tocopheryl carbonyl-5-fluorouracil were dissolved in one liter of O. D. O. (medium chain triglyceride produced and sold by Nisshin Oil Co., Ltd., Japan). This solution was put in a film of soft capsule of gelatine to obtain a suppository.
Claims (10)
1. A 5-fluorouracil derivative represented by the general formula: ##STR41## wherein R1, R2 and R3 each represent hydrogen or methyl, and R4 represents a straight or branched chain alkyl or alkenyl group.
2. The 5-fluorouracil derivative according to claim 1, wherein the derivative is N1 -α-tocopheryl carbonyl-5-fluorouracil.
3. The 5-fluorouracil derivative according to claim 1, wherein the derivative is N1 -β-tocopheryl carbonyl-5-fluorouracil.
4. The 5-fluorouracil derivative according to claim 1, wherein the derivative is N1 -γ-tocopheryl carbonyl-5-fluorouracil.
5. The 5-fluorouracil derivative according to claim 1, wherein the derivative is N1 -δ-tocopheryl carbonyl-5-fluorouracil.
6. The 5-fluorouracil derivative according to claim 1, wherein the derivative is N1 -α-tocotrienyl carbonyl-5-fluorouracil.
7. The 5-fluorouracil derivative according to claim 1, wherein the derivative is N1 -(2,2,5,7,8-pentamethyl chromanyl-6-carbonyl)-5-fluorouracil.
8. The 5-fluorouracil derivative according to claim 1, wherein the derivative is N1 -(2,5,7,8-tetramethyl-2-isohexyl chromanyl-6-carbonyl)-5-fluorouracil.
9. The 5-fluorouracil derivative according to claim 1, wherein the derivative is N1 -[2,5,7,8-tetramethyl-2-(4',8'-dimethylnonyl)-chromanyl-6-carbonyl]-5-fluorouracil.
10. An antitumor agent containing an effective anti-tumor amount of a 5-fluorouracil derivative represented by the general formula ##STR42## wherein R1, R2 and R3 each represent hydrogen or methyl, and R4 represents a straight or branched chain alkyl or alkenyl group having 1-16 carbons and a pharmaceutically acceptable carrier therefor.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP51-154941 | 1976-12-24 | ||
| JP51154941A JPS6052708B2 (en) | 1976-12-24 | 1976-12-24 | 5-Fluorouracil compounds and antitumor agents containing them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US4130648A true US4130648A (en) | 1978-12-19 |
Family
ID=15595270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US05/860,319 Expired - Lifetime US4130648A (en) | 1976-12-24 | 1977-12-14 | 5-Fluorouracil derivatives and antitumor preparations containing the same |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US4130648A (en) |
| JP (1) | JPS6052708B2 (en) |
| AU (1) | AU519524B2 (en) |
| BE (1) | BE862213A (en) |
| CA (1) | CA1077483A (en) |
| CH (1) | CH636874A5 (en) |
| DE (1) | DE2757431A1 (en) |
| ES (1) | ES465406A1 (en) |
| FR (1) | FR2378779A1 (en) |
| GB (1) | GB1594840A (en) |
| NL (1) | NL7714205A (en) |
| PH (1) | PH12700A (en) |
| SE (1) | SE436208B (en) |
| SU (2) | SU827489A1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4558127A (en) * | 1983-03-11 | 1985-12-10 | Emanuel Nikolai M | 5-Fluorouracil nitroxyl derivatives possessing antitumor activity |
| WO1987006581A1 (en) * | 1986-04-30 | 1987-11-05 | Farmaceutisk Laboratorium Ferring A/S | A prodrug form of 5-fluorouracil and a method of treatment of cancer |
| WO2019139921A1 (en) | 2018-01-09 | 2019-07-18 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
| US11034667B2 (en) | 2017-01-09 | 2021-06-15 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
| US11584733B2 (en) | 2017-01-09 | 2023-02-21 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4727077A (en) * | 1985-02-20 | 1988-02-23 | Ishihara Sangyo Kaisha Ltd. | Benzoyl urea compounds, process for their production, and antitumorous compositions containing them |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3971784A (en) * | 1973-11-28 | 1976-07-27 | Mitsui Pharmaceuticals, Incorporated | 5-Fluorouracil derivatives |
-
1976
- 1976-12-24 JP JP51154941A patent/JPS6052708B2/en not_active Expired
-
1977
- 1977-12-14 US US05/860,319 patent/US4130648A/en not_active Expired - Lifetime
- 1977-12-20 FR FR7738495A patent/FR2378779A1/en active Granted
- 1977-12-21 NL NL7714205A patent/NL7714205A/en not_active Application Discontinuation
- 1977-12-21 AU AU31825/77A patent/AU519524B2/en not_active Expired
- 1977-12-21 CH CH1581377A patent/CH636874A5/en not_active IP Right Cessation
- 1977-12-22 SE SE7714670A patent/SE436208B/en not_active IP Right Cessation
- 1977-12-22 GB GB53541/77A patent/GB1594840A/en not_active Expired
- 1977-12-22 BE BE183769A patent/BE862213A/en not_active IP Right Cessation
- 1977-12-22 DE DE19772757431 patent/DE2757431A1/en not_active Withdrawn
- 1977-12-23 SU SU772559705A patent/SU827489A1/en active
- 1977-12-23 PH PH20592A patent/PH12700A/en unknown
- 1977-12-23 CA CA293,822A patent/CA1077483A/en not_active Expired
- 1977-12-23 ES ES465406A patent/ES465406A1/en not_active Expired
-
1979
- 1979-06-18 SU SU792778129A patent/SU795469A3/en active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3971784A (en) * | 1973-11-28 | 1976-07-27 | Mitsui Pharmaceuticals, Incorporated | 5-Fluorouracil derivatives |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4558127A (en) * | 1983-03-11 | 1985-12-10 | Emanuel Nikolai M | 5-Fluorouracil nitroxyl derivatives possessing antitumor activity |
| WO1987006581A1 (en) * | 1986-04-30 | 1987-11-05 | Farmaceutisk Laboratorium Ferring A/S | A prodrug form of 5-fluorouracil and a method of treatment of cancer |
| US11034667B2 (en) | 2017-01-09 | 2021-06-15 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
| EP4046989A1 (en) | 2017-01-09 | 2022-08-24 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
| US11584733B2 (en) | 2017-01-09 | 2023-02-21 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
| WO2019139921A1 (en) | 2018-01-09 | 2019-07-18 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5379880A (en) | 1978-07-14 |
| ES465406A1 (en) | 1978-09-16 |
| SU795469A3 (en) | 1981-01-07 |
| FR2378779A1 (en) | 1978-08-25 |
| SE436208B (en) | 1984-11-19 |
| AU3182577A (en) | 1979-06-28 |
| FR2378779B1 (en) | 1980-08-22 |
| SU827489A1 (en) | 1981-05-07 |
| AU519524B2 (en) | 1981-12-10 |
| JPS6052708B2 (en) | 1985-11-20 |
| CA1077483A (en) | 1980-05-13 |
| BE862213A (en) | 1978-04-14 |
| CH636874A5 (en) | 1983-06-30 |
| NL7714205A (en) | 1978-06-27 |
| PH12700A (en) | 1979-07-20 |
| DE2757431A1 (en) | 1978-06-29 |
| GB1594840A (en) | 1981-08-05 |
| SE7714670L (en) | 1978-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0641767B1 (en) | Cytotoxic stilbene derivatives and pharmaceutical composition containing them | |
| JPH02111772A (en) | Beta-carboxylinic acid, benzofrane analogue and benzothiophene analogue and pharmaceutically acceptable acid addition salts thereof, and production thereof, composition having static cell characteristics and treatment of tumor | |
| KR840001965B1 (en) | Process for the preparation of anthracene-9,10-bis-carbonyl-hydrazones derivatives | |
| CN114516857A (en) | HPK1 inhibitors and uses thereof | |
| US4130648A (en) | 5-Fluorouracil derivatives and antitumor preparations containing the same | |
| US4886818A (en) | Inhibiting growth of tumors with certain substituted phenoxy dimethyl acids, esters or salts | |
| EP0129984B1 (en) | Novel 2'-deoxy-5-substituted uridine derivatives, processes for preparing the same and antitumor agent containing the same | |
| GB2173195A (en) | Pharmaceutical compositions | |
| US4636508A (en) | 5-pyrimidinecarboxyamides and treatment of leukemia therewith | |
| US4503045A (en) | 2'-Deoxy-3',5'-di-O-alkylcarbonyl-5-fluorouridine derivatives, a process for the preparation of the derivatives and anti-tumor agents containing the derivatives | |
| US5747502A (en) | Process for preparing benzo c!phenanthridinium derivatives, novel compounds prepared by said process, and antitumor agents | |
| RU2195451C2 (en) | Cyanoguanidines, methods of their synthesis and pharmaceutical preparation based on thereof | |
| HU217551B (en) | 6-[(2-hydroxyethyl)-amino-alkyl]-5,11-dioxo-5,6-dihydro-11-h-indeno(1,2-c)isoquinolin derivatives, process for producing them and pharmaceutical compositions containing them | |
| HUT63843A (en) | Process for producing new kumarin derivatives and their analogs inhibiting mammal cell proliferation and tumour growth, as well as pharmaceutical comkpositions comprising such compounds | |
| CA3102434C (en) | Selective a2a receptor antagonist | |
| US5210097A (en) | Xanthocillin x monomethyl ether derivative and antitumor agent containing the same | |
| DE3105111C2 (en) | ||
| JP4709387B2 (en) | Acyl derivatives of 4-demethylpenchromedin, their use and preparation | |
| US4241052A (en) | Novel nitrosourea compounds and process for preparing the same | |
| SU1301831A1 (en) | 9a-methoxymitosan 7-substituted derivatives possessing antitumoral activity | |
| US5250673A (en) | 2'-deoxy-5-substituted uridine derivatives | |
| EP0087951B1 (en) | Phenanthroline derivatives | |
| JPS6052750B2 (en) | 5-Fluorouracil compounds and antitumor agents comprising them | |
| EP0408384A1 (en) | N,N'-dicarboxymethyl, N,N'-dicarbamoylmethyl diaminoalkane derivatives and their use in pharmaceutical compositions. | |
| JPS61204172A (en) | 5-fluorouracil derivative |